Illumina, Inc. (ILMN)

Market Cap	20.09B
Revenue (ttm)	4.29B
Net Income (ttm)	703.00M
Shares Out	152.80M
EPS (ttm)	4.46
PE Ratio	29.47
Forward PE	26.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	965,739
Open	130.00
Previous Close	129.81
Day's Range	129.27 - 131.48
52-Week Range	68.70 - 153.06
Beta	1.45
Analysts	Hold
Price Target	114.93 (-12.57%)
Earnings Date	Oct 30, 2025

About ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 10,370
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN
• Website: https://www.illumina.com

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Analyst Summary

According to 15 analysts, the average rating for ILMN stock is "Hold." The 12-month stock price target is $114.93, which is a decrease of -12.57% from the latest price.

Price Target

$114.93

(-12.57% downside)

Analyst Consensus: Hold